drugset / Trial / NCT02105623
EARly Prevention of aTHeroma Progression
Phase 4
Terminated
111 enrolled
CHEOL WHAN LEE, M.D., Ph.D
CardioVascular Research Foundation, Korea · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare standard therapy (risk factor control, life style modification) versus standard therapy plus low-dose rosuvastatin therapy (5mg/day) on progression of coronary atherosclerosis in statin naive individuals who have mild CAD (nonobstructive coronary atherosclerotic plaques) and normal LDL (low-density lipoprotein) cholesterol levels(\<130mg/dl).
Timeline
- Start
- 2014-06
- Primary completion
- 2018-03
- Completion
- 2018-03
Outcome
Outcome not reported
Stopped (Enrollment): “Slow enrollement, Low Follow-up rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosuvastatin | Small molecule | 5 mg | — |